BR112022006583A2 - Formas cristalinas de estado sólido de um modulador de canal de potássio seletivo - Google Patents

Formas cristalinas de estado sólido de um modulador de canal de potássio seletivo

Info

Publication number
BR112022006583A2
BR112022006583A2 BR112022006583A BR112022006583A BR112022006583A2 BR 112022006583 A2 BR112022006583 A2 BR 112022006583A2 BR 112022006583 A BR112022006583 A BR 112022006583A BR 112022006583 A BR112022006583 A BR 112022006583A BR 112022006583 A2 BR112022006583 A2 BR 112022006583A2
Authority
BR
Brazil
Prior art keywords
potassium channel
solid
crystalline forms
channel modulator
selective potassium
Prior art date
Application number
BR112022006583A
Other languages
English (en)
Inventor
Robert Bichler Paul
A Cadieux Jean-Jacques
David Tandy Matthew
N Beatch Gregory
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of BR112022006583A2 publication Critical patent/BR112022006583A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Laminated Bodies (AREA)
  • Liquid Crystal Substances (AREA)
  • Transmitters (AREA)

Abstract

A presente invenção fornece formas de estado sólido de um modulador de canal de potássio seletivo e composições farmacêuticas compreendendo as formas cristalinas de estado sólido e excipientes farmaceuticamente aceitáveis, e métodos para preparar e usar as formas de estado sólido e as composições farmacêuticas das mesmas.
BR112022006583A 2019-10-10 2020-10-09 Formas cristalinas de estado sólido de um modulador de canal de potássio seletivo BR112022006583A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962913574P 2019-10-10 2019-10-10
PCT/US2020/055129 WO2021072307A1 (en) 2019-10-10 2020-10-09 Solid state crystalline forms of a selective potassium channel modulator

Publications (1)

Publication Number Publication Date
BR112022006583A2 true BR112022006583A2 (pt) 2022-06-28

Family

ID=73040296

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022006583A BR112022006583A2 (pt) 2019-10-10 2020-10-09 Formas cristalinas de estado sólido de um modulador de canal de potássio seletivo

Country Status (17)

Country Link
US (2) US11091441B2 (pt)
EP (1) EP4041713A1 (pt)
JP (1) JP2022552187A (pt)
KR (1) KR20220080119A (pt)
CN (1) CN115190874A (pt)
AU (1) AU2020364142A1 (pt)
BR (1) BR112022006583A2 (pt)
CA (1) CA3153752A1 (pt)
CL (1) CL2022000881A1 (pt)
CO (1) CO2022005890A2 (pt)
CR (1) CR20220187A (pt)
IL (1) IL292005A (pt)
MA (1) MA56288A1 (pt)
MX (1) MX2022004209A (pt)
PE (1) PE20221023A1 (pt)
TW (1) TW202128627A (pt)
WO (1) WO2021072307A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
AU2007288253B2 (en) * 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
KR20210020892A (ko) 2018-05-11 2021-02-24 제논 파마슈티칼스 인크. 전압 의존형 칼륨 채널 개방제의 생체 이용률 및 노출을 향상시키는 방법

Also Published As

Publication number Publication date
TW202128627A (zh) 2021-08-01
WO2021072307A1 (en) 2021-04-15
PE20221023A1 (es) 2022-06-16
CO2022005890A2 (es) 2022-05-31
MX2022004209A (es) 2022-05-03
AU2020364142A1 (en) 2022-04-21
IL292005A (en) 2022-06-01
US11091441B2 (en) 2021-08-17
KR20220080119A (ko) 2022-06-14
CA3153752A1 (en) 2021-04-15
MA56288A1 (fr) 2023-01-31
EP4041713A1 (en) 2022-08-17
US20220064120A1 (en) 2022-03-03
CR20220187A (es) 2022-07-21
CL2022000881A1 (es) 2023-01-13
CN115190874A (zh) 2022-10-14
JP2022552187A (ja) 2022-12-15
US20210147363A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
PE20151427A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2022000881A1 (es) Formas cristalinas de estado sólido de un modulador selectivo de canales de potasio
EP4003225A4 (en) BIOLOGICAL INK FORMULATIONS, BIO-PRINTED LENTICULUS AND RELATED APPLICATIONS
EA201792478A1 (ru) Соединения-ингибиторы передачи сигналов пути notch
PH12019501076A1 (en) Pharmaceutical formulations
EP3620129A4 (en) DENTAL APPARATUS FOR MAINTAINING A CARRIER'S TEETH ARRANGEMENT
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
IL276430A (en) A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use
CO2021003805A2 (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
CO2020004407A2 (es) Formulaciones de espora de nutriente y usos de las mismas
BR112017012646A2 (pt) Formas sólidas compreendendo (1e, 4e)-2-amino- n,n-dipropil-8-(4-(pirrolidina-1-carbonil) fenil)-3h- benzo[b]azepina-4-carboxamida, composições das mesmas, e uso das mesmas
CO2019009060A2 (es) Moduladores del canal de potasio
CO2022001783A2 (es) Formulaciones de cápsulas de cubierta blanda y métodos de preparación y uso de las mismas
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
CL2021002512A1 (es) Formulaciones liposomales y métodos para usar y preparar las mismas.
EP3999089A4 (en) ANTICOCCIDAL PHYTOGENIC FORMULATIONS
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
MX2021014806A (es) Composiciones para el cuidado bucal y sus usos.
EA201992844A1 (ru) Новые пероральные составы на основе белиностата
WO2019014286A3 (en) IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF
EP3585397A4 (en) ORAL AMPHOTERICIN B SOLID FORMULATIONS
SG11201907124YA (en) Anti-inflammatory agent